- Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
- Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
- Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
- Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
- Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
- Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
- Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
- Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
- Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
More ▼
Key statistics
As of last trade, Alterity Therapeutics Ltd (ATH:ASX) traded at 0.005, 66.67% above the 52 week low of 0.003 set on Nov 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.005 |
---|---|
High | 0.005 |
Low | 0.005 |
Bid | 0.004 |
Offer | 0.005 |
Previous close | 0.004 |
Average volume | 3.20m |
---|---|
Shares outstanding | 5.25bn |
Free float | 4.88bn |
P/E (TTM) | -- |
Market cap | 20.98m AUD |
EPS (TTM) | -0.005 AUD |
Data delayed at least 20 minutes, as of Jul 04 2024 00:59 BST.
More ▼